Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Xilio Therapeutics (XLO)

Xilio Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:XLO
DateTimeSourceHeadlineSymbolCompany
13/06/202421:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
13/06/202421:05GlobeNewswire Inc.Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of DirectorsNASDAQ:XLOXilio Therapeutics Inc
14/05/202413:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XLOXilio Therapeutics Inc
14/05/202412:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
14/05/202412:30GlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
07/05/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:XLOXilio Therapeutics Inc
01/04/202421:05GlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
28/03/202411:05GlobeNewswire Inc.Xilio Therapeutics Announces $11.3 Million Private Placement Equity FinancingNASDAQ:XLOXilio Therapeutics Inc
28/03/202411:00GlobeNewswire Inc.Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:XLOXilio Therapeutics Inc
28/03/202411:00Business WireGilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:XLOXilio Therapeutics Inc
28/02/202421:01GlobeNewswire Inc.Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care ConferenceNASDAQ:XLOXilio Therapeutics Inc
31/01/202421:01GlobeNewswire Inc.Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology ConferenceNASDAQ:XLOXilio Therapeutics Inc
19/01/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
08/01/202412:30GlobeNewswire Inc.Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology TherapiesNASDAQ:XLOXilio Therapeutics Inc
03/01/202421:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
03/01/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
03/01/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
03/01/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
07/12/202312:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
07/12/202312:30GlobeNewswire Inc.Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy DataNASDAQ:XLOXilio Therapeutics Inc
09/11/202321:17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XLOXilio Therapeutics Inc
09/11/202321:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
09/11/202321:10Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:XLOXilio Therapeutics Inc
09/11/202321:08Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:XLOXilio Therapeutics Inc
09/11/202321:05Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:XLOXilio Therapeutics Inc
09/11/202321:01GlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
03/11/202320:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
03/11/202316:00GlobeNewswire Inc.Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid TumorsNASDAQ:XLOXilio Therapeutics Inc
31/10/202313:15GlobeNewswire Inc.Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual MeetingNASDAQ:XLOXilio Therapeutics Inc
27/09/202322:02GlobeNewswire Inc.Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:XLOXilio Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:XLO